Skip to main content

Table 3 Sensitivity analysis for incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with diabetes who completed more than 1 year follow-up periods after index date

From: Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study

 

Aspirin non-user

Low-dose aspirin user

  
 

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Crude Hazard Ratio (95% CI)

Adjusted Hazard Ratio * (95% CI)

Whole matched cohort

84

48,553

1.7

139

44,527

3.1

1.85 (1.41-2.44)

1.97 (1.51-2.62)

Gender

Male

42

27,476

1.5

78

25,182

3.1

3.01 (2.12-4.28)

3.25 (2.28-4.63)

 

Female

42

21,077

2.0

61

19,345

3.2

1.65 (1.65-2.45)

1.72 (1.16-2.57)

Age

40-69

48

39,633

1.2

85

37,019

2.3

1.98 (1.98-2.62)

2.12 (1.48-3.03)

 

70-99

36

8,921

4.0

54

7,508

7.2

1.79 (1.79-2.74)

1.89 (1.23-2.91)

Type of diabetes

Type 1 only

8

3,064

2.6

8

2,282

3.5

1.32 (0.50-3.52)

1.38 (0.50-3.77)

 

Type 2 and others

76

45,489

1.7

131

42,245

3.1

1.91 (1.44-2.54)

2.05 (1.54-2.74)

Diabetes with essential hypertension

Yes

48

24,669

1.9

82

21,272

3.9

2.03 (1.42-2.91)

2.14 (1.50-3.07)

No

36

23,885

1.5

57

23,225

2.5

1.67 (1.09-2.54)

1.78 (1.16-2.73)

Diabetes with dyslipidemia

Yes

24

13,444

1.8

27

11,240

2.4

1.34 (0.78-2.34)

1.60 (0.92-2.82)

No

60

35,109

1.7

112

33,287

3.4

2.04 (1.49-2.80)

2.13 (1.55-2.93)

  1. CI: confidence interval.
  2. *Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.